Ignatz-Hoover JJ - Search Results

1

Aberrant GSK3β nuclear localization promotes AML growth and drug resistance.

Ignatz-Hoover JJ, Wang V, Mackowski NM, Roe AJ, Ghansah IK, Ueda M, Lazarus HM, de Lima M, Paietta E, Fernandez H, Cripe L, Tallman M, Wald DN. Ignatz-Hoover JJ, et al. Blood Adv. 2018 Nov 13;2(21):2890-2903. doi: 10.1182/bloodadvances.2018016006. Blood Adv. 2018. PMID: 30385433 Free PMC article.

2

The role of TLR8 signaling in acute myeloid leukemia differentiation.

Ignatz-Hoover JJ, Wang H, Moreton SA, Chakrabarti A, Agarwal MK, Sun K, Gupta K, Wald DN. Ignatz-Hoover JJ, et al. Leukemia. 2015 Apr;29(4):918-926. doi: 10.1038/leu.2014.293. Epub 2014 Oct 6. Leukemia. 2015. PMID: 25283842 Free PMC article.

3

GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation.

Gupta K, Stefan T, Ignatz-Hoover J, Moreton S, Parizher G, Saunthararajah Y, Wald DN. Gupta K, et al. Cancer Res. 2016 May 1;76(9):2743-53. doi: 10.1158/0008-5472.CAN-15-2290. Epub 2016 Mar 10. Cancer Res. 2016. PMID: 26964622 Free PMC article.

4

A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.

Hu S, Ueda M, Stetson L, Ignatz-Hoover J, Moreton S, Chakrabarti A, Xia Z, Karan G, de Lima M, Agrawal MK, Wald DN. Hu S, et al. Mol Cancer Ther. 2016 Jul;15(7):1485-1494. doi: 10.1158/1535-7163.MCT-15-0566. Epub 2016 May 9. Mol Cancer Ther. 2016. PMID: 27196775 Free PMC article.

5

Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia.

Ueda M, Stefan T, Stetson L, Ignatz-Hoover JJ, Tomlinson B, Creger RJ, Cooper B, Lazarus HM, de Lima M, Wald DN, Caimi PF. Ueda M, et al. Front Oncol. 2020 Mar 10;10:327. doi: 10.3389/fonc.2020.00327. eCollection 2020. Front Oncol. 2020. PMID: 32211336 Free PMC article.

6

Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases.

Rana PS, Ignatz-Hoover JJ, Driscoll JJ. Rana PS, et al. Among authors: ignatz hoover jj. Cancers (Basel). 2023 Nov 29;15(23):5632. doi: 10.3390/cancers15235632. Cancers (Basel). 2023. PMID: 38067336 Free PMC article. Review.

7

Novel therapies emerging in oncology to target the TGF-β pathway.

Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Kim BG, et al. Among authors: ignatz hoover jj. J Hematol Oncol. 2021 Apr 6;14(1):55. doi: 10.1186/s13045-021-01053-x. J Hematol Oncol. 2021. PMID: 33823905 Free PMC article. Review.

8

The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial.

Malek E, Rana PS, Swamydas M, Daunov M, Miyagi M, Murphy E, Ignatz-Hoover JJ, Metheny L, Kim SJ, Driscoll JJ. Malek E, et al. Among authors: ignatz hoover jj. Nat Commun. 2024 Aug 27;15(1):7388. doi: 10.1038/s41467-024-51442-2. Nat Commun. 2024. PMID: 39191755 Free PMC article. Clinical Trial.

9

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.

Swamydas M, Murphy EV, Ignatz-Hoover JJ, Malek E, Driscoll JJ. Swamydas M, et al. Among authors: ignatz hoover jj. J Hematol Oncol. 2022 Feb 16;15(1):17. doi: 10.1186/s13045-022-01234-2. J Hematol Oncol. 2022. PMID: 35172851 Free PMC article. Review.

10

Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes.

Ignatz-Hoover JJ, Murphy EV, Driscoll JJ. Ignatz-Hoover JJ, et al. Front Cell Infect Microbiol. 2022 Jul 7;12:925804. doi: 10.3389/fcimb.2022.925804. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35873166 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters